BrainStorm rises on deal with US FDA on study design for ALS therapy

Brainstorm Cell Therapeutics

09/04/2024 12:14

** Shares of BrainStorm Cell Therapeutics  BCLI.O  rise 6.6%
to 77 cents premarket     
    ** Co says it has entered into an agreement with the U.S.
Food and Drug Administration on the design for a late-stage
study testing its ALS therapy NurOwn
    ** ALS, or amyotrophic lateral sclerosis, is a rare and
fatal neurodegenerative disease, which affects voluntary control
of arms and legs, and leads to breathing trouble
    ** Last year, advisers to the FDA voted against the cell
therapy, citing lack of substantial evidence to prove its
effectiveness to treat mild-to-moderate ALS       
    ** BCLI plans to begin the study this year and will enroll
participants earlier in the course of their disease
    ** Up to last close, BCLI shares down 74% in the past 12
months 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))